Entera Bio Ltd. Ordinary Shares (ENTX)

About Entera Bio Ltd. Ordinary Shares

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 26 institutions reported holding ENTX, with 10.7 million shares worth $18.9 million in aggregate. The largest reported holder was Knoll Capital Management, with 5.9 million shares worth $10.4 million. Of the 5 largest holders listed below, 2 opened new positions in ENTX, 2 reduced their positions and 1 held its position unchanged during the quarter.

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions